ClinicalTrials.gg
TerminatedNCT03367689NOBROLAUpdated Feb 22, 2023

A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent

A Phase 2 interventional study of Olaparib in Breast Cancer, sponsored by MedSIR. Terminated at 5 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-22.

Sponsored by MedSIR · Phase 2, Interventional, and Treatment

Why this study was terminated
Very slow recruitment due to subject profile

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing olaparib in Breast Neoplasms — 11 open to participants now, 25 under way, 4 of them phase 3. olaparib · Breast Neoplasms.

Enrollment
45th of 51
7 · median 54
Started
2018
with 3 others
Phase 2
24 of 51
7 open now
Registered
25th of 51
by date
Lead sponsor
2 of 51
MedSIR

Among the 51 studies testing olaparib in Breast Neoplasms, this one is the 45th largest by enrollment, is one of 4 that started in 2018, is one of 24 in phase 2, and was the 25th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 51 studies testing olaparib in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing olaparib in Breast Neoplasms, or all of them as a file.
02

Study summary

This is an international, multi-centre, non-controlled, open-label, single arm, two-stage Simon Design phase II study for non-BRCA metastatic breast cancer (MBC) patients with homologous recombination deficiency treated with Olaparib single agent.

The main objective is to assess the efficacy of olaparib single agent as determined by Clinical Benefit Rate (CBR) using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

In the first stage Triple negative (TN) non-BRCA, metastatic breast cancer (MBC) patients whose tumours exhibited any characteristic related to homologous recombination deficiency (HRD). In the second stage, luminal patients (RH positive HER2 negative) will be allowed in the same conditions that TN.

Patients whose tumours are identified as Homologous Recombination Deficient by deleterious HRR gene mutations (according to Foundation Medicine's Foundation One assay) will receive olaparib 300 mg (two tablets of 150mg) orally twice daily (bid) on days 1-28 each 28 days.

Study commitment is 39 patients: 17 patients will be enrolled at first stage and 22 at the second stage.

The total duration of the study period is 34 months.

Read the detailed description

This is an international, multi-centre, non-controlled, open-label, single arm, two-stage Simon Design phase II study for non-BRCA metastatic breast cancer (MBC) patients with homologous recombination deficiency treated with Olaparib single agent.

The main objective is to assess the efficacy of olaparib single agent as determined by Clinical Benefit Rate (CBR) using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

Triple negative non-BRCA metastatic breast cancer women (for the first stage) age ≥ 18 years that had previously received at least one (and no more than three) line for their metastatic disease. Patients must have previously received taxanes either in the early or in the metastatic scenario. To be included in the trial, tumours must be considered homologous recombination deficient (HRD) according to Foundation Medicine's Foundation One assay. Evidence of measurable metastatic disease is required.

In the second stage, luminal patients (RH positive HER2 negative) will be allowed to participate in the same conditions that TN patients.

Patients whose tumours are identified as Homologous Recombination Deficient by deleterious HRR gene mutations (according to Foundation Medicine's Foundation One assay) will receive olaparib 300 mg (two tablets of 150mg) orally twice daily (bid) on days 1-28 each 28 days.

Study commitment is 39 patients: 17 patients will be enrolled at first stage and 22 at the second stage.

During the period between the end of the first stage and the beginning of the second, an interim analysis will be conducted to assess the viability of the second part of the trial.

The total duration of the study period is 34 months.

Stage I:

  • Recruitment period: 10 months
  • Follow-up period: Up to 6 months after last patient included in the study

Stage II:

  • Recruitment period: 12 months
  • Follow-up period: up to 6 months after last patient included in the study
03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are eligible for inclusion only if they meet ALL the following criteria:

  1. Female patients ≥ 18 years of age.
  2. (ECOG) score lower or equal to 1.
  3. greater or equal to 16 weeks.
  4. Confirmed TN locally advanced or breast cancer in the first stage. For the second stage, luminal-like patients (RH-positive -negative) will be allowed.
  5. Wild type BRCA1 and BRCA2 (germline). Variants with unknown significance are eligible.
  6. Tumors must exhibit a HRD signature according to Foundation Medicine's Foundation One assay. Formalin fixed, paraffin embedded (FFPE) tumor sample from the metastatic cancer must be available for central testing. If there is not written confirmation of the availability of an archived tumor sample prior to enrolment the patient is not eligible for the study.
  7. No more than three (and at least one) previous lines for the metastatic disease. Previous treatment must include taxanes (neo/adjuvant scenario is also possible) if not formally .
  8. Patient must have according to 1.1 criteria. At least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis > or equal 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements.
  9. Patients must have normal organ and bone marrow function measured within 35 days prior to administration of study treatment as defined below:

    Hematological: White blood cell (WBC) count >3.0 x 109/L, (ANC) > or equal 1.5 x 109/L, count ≥100.0 x109/L, and >10.0 g/dL (>6.2 mmol/L) with no blood transfusion in the past 35 days.

    Hepatic: ≤ 1.5 times the (x ULN); alkaline phosphatase (ALP), (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) \< or equal 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be \< or equal 5x ULN.

    Renal: estimated using the Cockcroft-Gault equation of > or equal 51 mL/min

  10. Patient has been informed about the nature of study, and has agreed to participate, and signed the form (ICF) prior to participation in any study-related activities
  11. No other within the past five years except adequate treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
  12. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCICTCAE version 4.03 Grade \< or equal 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).
  13. or evidence of non-childbearing status for women of : negative urine or serum pregnancy test within 28 days prior to administration of study treatment and confirmed prior to treatment on day 1. Postmenopausal is defined as:

Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments; Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the post-menopausal range for women under 50; Radiation-induced oophorectomy with last menses >1 year ago; Chemotherapy-induced menopause with >1 year interval since last menses; Surgical sterilization (bilateral oophorectomy or hysterectomy).

Exclusion criteria

Exclusion Criteria:

Patients will be excluded from the study if they meet ANY of the following criteria:

  1. RH-positive (based on local laboratory results) or unknown for the first stage. In the second stage, luminal-like -negative patients will be allowed.
  2. HER2-positive (based on local laboratory results [performed by immunohistochemistry/fluorescence in situ hybridization (FISH)] or unknown.
  3. Locally advanced breast cancer candidate for a radical treatment.
  4. Has deleterious germline BRCA1 or BRCA2 mutation as determined by local test.
  5. Patients with symptomatic uncontrolled . A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 35 days.
  6. Patients with symptomatic visceral disease are not eligible.
  7. Other within the last 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma, or other solid tumors including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.
  8. Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML
  9. Have had a major surgery (defined as requiring general anesthesia) or significant traumatic injury within 2 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery or patients that may require major surgery during the course of the study.
  10. Resting with > 470 msec on 2 or more time points within a 24-hour period or family history of long QT syndrome.
  11. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment
  12. Concomitant use of known strong inhibitors or moderate CYP3A inhibitors. The required prior to starting olaparib is 2 weeks.
  13. Concomitant use of known strong or moderate CYP3A inducers. The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
  14. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining .
  15. patients, e.g., patients who are known to be serologically positive for (HIV).
  16. Patients with known active hepatitis (i.e. or C).
  17. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).
  18. Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and transfusions are acceptable, for timing refer to inclusion criteria no.9).
  19. Are unable to swallow orally administered medication.
  20. Patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  21. Chronic daily treatment with corticosteroids with a dose of ≥ 10mg/day methylprednisolone equivalent (excluding inhaled steroids), except for prophylaxis use.
  22. Female patients who are pregnant or breastfeeding, or adults of who are not using effective methods.
  23. Patients unwilling to or unable to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
  24. Patients that have previously receive any PARP inhibitor for any reason, including olaparib.
  25. Known to olaparib or any of the excipients of the product.
  26. Involvement in the planning and/or conduct of the study (applies to both sponsor staff and/or staff at the study site).
  27. Previous enrolment in the present study.
  28. Participation in another clinical study with an product during the last 3 weeks.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Olaparib 300 mg

    Patients whose tumours are identified as Homologous Recombination Deficient, will receive olaparib 300 mg (two tablets of 150mg) orally twice daily (bid) on days 1-28 each 28 days.

    Drug: Olaparib

Interventions

  • Olaparib 300 mg twice a day (orally) beginning on Day 1 and continuing through Day 28 of every 28-day cycle.

    Also known as: Lynparza, AZD2281

06

What researchers measure

Primary outcomes

  1. To assess the efficacy of olaparib single agent in non-BRCA MBC patients whose tumours exhibit an homologous recombination deficiency (HRD) signature, as determined by Clinical Benefit Rate (CBR) using RECIST 1.1 criteria

    The CBR as best response, defined as the percentage of patients who experience a complete response, partial response or stable disease for at least 24 weeks and assessed by modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteria

    Time frame: Baseline up to 24 weeks

Secondary outcomes

  1. To assess the accuracy of Foundation One's HRR assay in predicting the proportion of patients with response to olaparib.

    The positive predictive value (PPV) of the signature to predict patients that achieved objective response and clinical benefit.

    Time frame: Baseline up to 34 months

  2. To assess incidence of Treatment-Emergent Adverse Events (Safety profile) of olaparib in this population

    This study will consider the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v4.03 criteria) grade 3 and 4 events (AEs) and serious AEs (SAEs) in order to assess the safety and tolerability objectives.

    Time frame: Baseline up to 34 months

  3. To investigate the prevalence of HRD signature within triple negative and luminal non-BRCA patients' cohorts

    The percentage of patients with HRD according to the Foundation Medicine's Foundation One assay within triple negative and luminal (in the second stage) non-BRCA patients' cohorts

    Time frame: Baseline up to 34 months

  4. To explore the efficacy of olaparib in terms of Progression-free survival (PFS)

    The PFS defined as the time from the first dose of study drugs until objective tumour progression or death, as assessed by the investigator per RECIST v1.1.

    Time frame: Baseline up to 34 months

  5. To explore the efficacy of olaparib in terms of objective response rate (ORR)

    The ORR defined as the proportion of patients with best objective response of confirmed complete response (CR) or partial response (PR) according to RECIST criteria guidelines (version 1.1).

    Time frame: Baseline up to 34 months

  6. To explore the efficacy of olaparib in terms of overall survival (OS)

    The OS defined as the time from the first dose of study drugs until death from any cause or the last date the patient was known to be alive.

    Time frame: Baseline up to 34 months

07

Study locations

5 sites
  • Hospital del Mar
    Barcelona, Spain
  • Onkologikoa
    Donostia, Spain
  • Institut Català d' Oncologia L'Hospitalet (ICO)
    L'Hospitalet De Llobregat, Spain
  • Hospital Ramón y Cajal
    Madrid, Spain
  • Hospital Arnau de Vilanova de Valencia
    Valencia, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Jul 2021, 39 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2017
First posted
Dec 11, 2017
StartActual
Apr 17, 2018
Primary completionActual
Jul 31, 2021
CompletionActual
Dec 31, 2021
Last update
Feb 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03367689
Lead sponsor
MedSIR
Responsible party
Sponsor
First posted
Dec 11, 2017
Start date
Apr 17, 2018
Primary completion
Jul 31, 2021
Completion
Dec 31, 2021
Last update
Feb 22, 2023

Study contacts

Javier Cortes
principal investigator · Hospital Universitario Ramon y Cajal

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion